

Archived Content



The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Proton Pump Inhibitors Information

Proton pump inhibitors (PPIs) are used to treat certain gastrointestinal disorders and work by reducing the amount of acid in the stomach. They are available both as prescription and as over-the-counter (OTC) medications.

Current Safety Information

- **FDA Drug Safety Communication: Clostridium difficile - associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs) (/Drugs/DrugSafety/ucm290510.htm)**
2/8/2012
- **FDA Drug Safety Podcast for Healthcare Professionals: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs) (/Drugs/DrugSafety/DrugSafetyPodcasts/ucm291058.htm)**
2/8/2012
- **Lansoprazole - Letter to Healthcare Professionals: Communication on lansoprazole delayed-release orally disintegrating tablets manufactured by Teva Pharmaceuticals (/Drugs/DrugSafety/ucm251485.htm)** [ARCHIVED]
4/15/2011
- **FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs) (/Drugs/DrugSafety/ucm245011.htm)** [ARCHIVED]
3/2/2011
- **FDA Drug Safety Podcast: Risk of Low Magnesium Levels Associated with Long-Term Use of Proton Pump Inhibitors (/Drugs/DrugSafety/DrugSafetyPodcasts/ucm246866.htm)** [ARCHIVED]
3/11/2011
- **FDA Drug Safety Podcast for Healthcare Professionals: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs) (/Drugs/DrugSafety/DrugSafetyPodcasts/ucm245455.htm)** [ARCHIVED]
3/2/2011
- **FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors (/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm)** [ARCHIVED]
5/25/2010; updated 3/23/2011
- **FDA: Possible Fracture Risk with High Dose, Long-term Use of Proton Pump Inhibitors (/NewsEvents/Newsroom/PressAnnouncements/2010/ucm213377.htm)** [ARCHIVED]
FDA press release (5/25/2010)
- **Proton Pump Inhibitors (PPI): Class Labeling Change (/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm213321.htm)**
MedWatch information (5/25/2010)
- **Possible Increased Risk of Bone Fractures With Certain Antacid Drugs (/ForConsumers/ConsumerUpdates/ucm213240.htm)** [ARCHIVED]
FDA consumer update
- **Podcast for Healthcare Professionals: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors (/Drugs/DrugSafety/DrugSafetyPodcasts/ucm214472.htm)** [ARCHIVED]
5/28/2010

Previous Communications

- **Update of Safety Review - Follow-up to the August 9, 2007, Communication about the Ongoing Safety Review of Omeprazole and Esomeprazole** (</Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm143258.htm>) [ARCHIVED]
12/10/2007
- **FDA's Safety Reviews of Prilosec and Nexium Find No Evidence of Increased Rates of Cardiac Events** (</NewsEvents/Newsroom/PressAnnouncements/2007/ucm109037.htm>) [ARCHIVED]
12/10/2007
- **Early Communication About an Ongoing Safety Review of Omeprazole (Prilosec) and Esomeprazole (Nexium)** (</Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm072497.htm>) [ARCHIVED]
8/9/2007
- **Prilosec OTC (omeprazole) Information** (</AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm220944.htm>)

Contact FDA

1-800-332-1088
1-800-FDA-0178 Fax

Report a Serious Problem

MedWatch Online (<https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm>)

Regular Mail: Use postage-paid **FDA Form 3500** (<http://www.fda.gov/downloads/Safety/MedWatch/DownloadForms/UCM082725.pdf>)

Mail to: MedWatch 5600 Fishers Lane
Rockville, MD 20857